Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Biotechnol ; 25(10): 1134-43, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17921999

ABSTRACT

Therapeutic monoclonal antibodies have shown limited efficacy and safety owing to immunogenicity of mouse sequences in humans. Among the approaches developed to overcome these hurdles were transgenic mice genetically engineered with a 'humanized' humoral immune system. One such transgenic system, the XenoMouse, has succeeded in recapitulating the human antibody response in mice, by introducing nearly the entire human immunoglobulin loci into the germ line of mice with inactivated mouse antibody machinery. XenoMouse strains have been used to generate numerous high-affinity, fully human antibodies to targets in multiple disease indications, many of which are progressing in clinical development. However, validation of the technology has awaited the recent regulatory approval of panitumumab (Vectibix), a fully human antibody directed against epidermal growth factor receptor (EGFR), as treatment for people with advanced colorectal cancer. The successful development of panitumumab represents a milestone for mice engineered with a human humoral immune system and their future applications.


Subject(s)
Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/metabolism , Antineoplastic Agents/metabolism , Animals , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibody Diversity , Antibody Formation , Antibody Specificity , Clinical Trials as Topic , Colorectal Neoplasms/drug therapy , ErbB Receptors , Genes, Immunoglobulin , Genetic Engineering , Humans , Mice , Mice, Transgenic , Panitumumab
2.
Cancer Res ; 67(12): 5798-805, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17575147

ABSTRACT

Six-transmembrane epithelial antigen of the prostate-1 (STEAP-1) is a novel cell surface protein highly expressed in primary prostate cancer, with restricted expression in normal tissues. In this report, we show STEAP-1 expression in prostate metastases to lymph node and bone and in the majority of human lung and bladder carcinomas. We identify STEAP-1 function in mediating the transfer of small molecules between adjacent cells in culture, indicating its potential role in tumor cell intercellular communication. The successful generation of two monoclonal antibodies (mAb) that bind to cell surface STEAP-1 epitopes provided the tools to study STEAP-1 susceptibility to naked antibody therapy. Both mAbs inhibited STEAP-1-induced intercellular communication in a dose-dependent manner. Furthermore, both mAbs significantly inhibited tumor growth in mouse models using patient-derived LAPC-9 prostate cancer xenografts and established UM-UC-3 bladder tumors. These studies validate STEAP-1 as an attractive target for antibody therapy in multiple solid tumors and provide a putative mechanism for mAb-induced tumor growth inhibition.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antigens, Neoplasm/drug effects , Cell Communication/drug effects , Oxidoreductases/drug effects , Prostatic Neoplasms/metabolism , Animals , Antigens, Neoplasm/metabolism , Blotting, Western , Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Flow Cytometry , Humans , Immunohistochemistry , In Vitro Techniques , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Lymphatic Metastasis/pathology , Male , Mice , Neoplasm Transplantation , Oxidoreductases/metabolism , Prostatic Neoplasms/pathology , RNA, Small Interfering , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/secondary , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...